{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:27:18Z","timestamp":1787315238060,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.coms.2007.01.005","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T08:54:55Z","timestamp":1180083295000},"page":"199-206","source":"Crossref","is-referenced-by-count":17,"title":["Osteonecrosis and Bisphosphonates in Oral and Maxillofacial Surgery"],"prefix":"10.1016","volume":"19","author":[{"given":"Ahmad N.","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore L.","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coms.2007.01.005_bib1","unstructured":"Marx RE, Stern D. Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Carol Stream (IL): Quintessence; 2003. p. 36\u20138."},{"key":"10.1016\/j.coms.2007.01.005_bib2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","article-title":"Osteonecrosis of the jaws associated with cancer chemotherapy","volume":"61","author":"Wang","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib3","first-page":"795","article-title":"Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report","volume":"22","author":"Mehrotra","year":"2003","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1016\/j.coms.2007.01.005_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0278-2391(03)00566-4","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates","volume":"61","author":"Rosenberg","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib6","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphonates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coms.2007.01.005_bib7","first-page":"268","article-title":"Bisphosphonates and avascular necrosis of the jaws","volume":"48","author":"Carter","year":"2003","journal-title":"Aust Dent J"},{"key":"10.1016\/j.coms.2007.01.005_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.tripleo.2004.02.014","article-title":"Osteonecrosis of the maxilla and mandible: possible drug-induced complication of bisphosphonate therapy","volume":"97","author":"Estillo","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.coms.2007.01.005_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.joms.2004.03.005","article-title":"Osteonecrosis and bisphosphonates: correlation versus causation","volume":"62","author":"Schwartz","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib11","first-page":"191","article-title":"Ten years of alendronate treatment for osteoporosis in postmenopausal women","volume":"351","author":"Ruggiero","year":"2004","journal-title":"N Engl J Med"},{"issue":"4 Suppl","key":"10.1016\/j.coms.2007.01.005_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.47102\/annals-acadmedsg.V33N4p48S","article-title":"Bisphosphonates: a word of caution","volume":"33","author":"Robinson","year":"2004","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.coms.2007.01.005_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tripleo.2004.06.013","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonate medications: a report of 60 cases","volume":"98","author":"Ruggiero","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.coms.2007.01.005_bib14","first-page":"440","article-title":"Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity","volume":"117","author":"Lugassy","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.coms.2007.01.005_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.tripleo.2004.08.001","article-title":"Intravenous bisphosphonates and osteonecrosis","volume":"93","author":"Greenberg","year":"2004","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"11","key":"10.1016\/j.coms.2007.01.005_bib16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V104.11.756.756","article-title":"Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia and Zometa use","volume":"104","author":"Durie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJM200502243520823","article-title":"Multiple myeloma","volume":"352","author":"Altundag","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coms.2007.01.005_bib18","first-page":"841","article-title":"Multiple myeloma","volume":"352","author":"Kyle","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coms.2007.01.005_bib19","first-page":"111","article-title":"Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy","volume":"71","author":"Melo","year":"2005","journal-title":"J\u00a0Can Dent Assoc"},{"key":"10.1016\/j.coms.2007.01.005_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0714.2004.00269.x","article-title":"Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases","volume":"34","author":"Bagan","year":"2005","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.coms.2007.01.005_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tripleo.2004.10.001","article-title":"Bisphosphonate-associated oral osteonecrosis","volume":"99","author":"Migliorati","year":"2005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.coms.2007.01.005_bib22","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"128","author":"Vannucchi","year":"2005","journal-title":"Br J Hematol"},{"key":"10.1016\/j.coms.2007.01.005_bib23","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","article-title":"Bisphosphonates and avascular necrosis of the jaw: a possible association","volume":"182","author":"Carter","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.coms.2007.01.005_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw: Adverse Drug Reactions Advisory Report","volume":"182","author":"Purcell","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.coms.2007.01.005_bib25","unstructured":"Abramowicz M, editor. Alendronate (Fosamax) and risedronate (Actonel) revisited. Med Lett Drugs Ther 2005;47(1207):33\u201335."},{"key":"10.1016\/j.coms.2007.01.005_bib26","first-page":"385","article-title":"Ethical dilemma #51: Dealing with uncertainty: bisphosphonate-related osteonecrosis","volume":"122","author":"Hasegawa","year":"2005","journal-title":"Tex Dent J"},{"key":"10.1016\/j.coms.2007.01.005_bib27","first-page":"163","article-title":"Nonhealing extraction site","volume":"53","author":"Philipone","year":"2005","journal-title":"Gen Dent"},{"key":"10.1016\/j.coms.2007.01.005_bib28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.coms.2007.01.005_bib29","first-page":"181","article-title":"Bisphosphonates, cancer and osteonecrosis: a single practice experience","volume":"77","author":"Guarino","year":"2005","journal-title":"Del Med J"},{"key":"10.1016\/j.coms.2007.01.005_bib30","first-page":"12","article-title":"Osteonecrosis warning: cancer drugs preclude some dental procedures","author":"Hellstein","year":"2005","journal-title":"American Dental Association News, May 16,"},{"key":"10.1016\/j.coms.2007.01.005_bib31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.bdj.4812376","article-title":"Special precautions","volume":"198","author":"Nelson","year":"2005","journal-title":"Br Dent J"},{"key":"10.1016\/j.coms.2007.01.005_bib32","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1503\/cmaj.050640","article-title":"Patients receiving intravenous bisphosphonates should avoid invasive dental procedures","volume":"172","author":"Wooltorton","year":"2005","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.coms.2007.01.005_bib33","first-page":"31","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates","volume":"10","author":"Ruggiero","year":"2005","journal-title":"Bulletin of the Nassau County Dental Society"},{"issue":"3","key":"10.1016\/j.coms.2007.01.005_bib34","first-page":"4","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"21","author":"Johnson","year":"2005","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.coms.2007.01.005_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2007.01.005_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coms.2007.01.005_bib37","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Woo","year":"2005","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.coms.2007.01.005_bib38","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coms.2007.01.005_bib39","first-page":"101","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Tarassoff","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.coms.2007.01.005_bib40","first-page":"E88","article-title":"Bisphosphonates as a new cause of drug-induced jaw osteonecrosis: an update","volume":"10","author":"Jimenez-Soriano","year":"2005","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.coms.2007.01.005_bib41","first-page":"239","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"9","author":"Schrimer","year":"2005","journal-title":"Mund Kiefer Gesichtschir"},{"key":"10.1016\/j.coms.2007.01.005_bib42","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/annonc\/mdi206","article-title":"Jaw avascular bone necrosis associated with long-term use of bisphosphonates","volume":"16","author":"Sanna","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coms.2007.01.005_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5694\/j.1326-5377.2005.tb06970.x","article-title":"Bisphosphonates and osteonecrosis: analogy to phossy jaw","volume":"183","author":"Donoghue","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.coms.2007.01.005_bib44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.urology.2005.03.028","article-title":"Osteonecrosis of the jaw in a patient with hormone-refractory prostate cancer treated with zoledronic acid","volume":"66","author":"Olson","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.coms.2007.01.005_bib45","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1055\/s-2005-916355","article-title":"Osteonecrosis of the jaws during treatment with bisphosphonates: diagnosis and therapeutic options","volume":"130","author":"Steiner","year":"2005","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.coms.2007.01.005_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.don.0000182737.09980.2c","article-title":"Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports","volume":"31","author":"Sarathy","year":"2005","journal-title":"J Endod"},{"key":"10.1016\/j.coms.2007.01.005_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.291.291","article-title":"Bisphosphonate related osteonecrosis (BRON) of the jaw: single institutional update","volume":"106","author":"Mehrotra","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0749-0690(02)00069-1","article-title":"Bisphosphonate treatment of osteoporosis","volume":"19","author":"Watts","year":"2003","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.coms.2007.01.005_bib49","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berensen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coms.2007.01.005_bib50","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.coms.2007.01.005_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","article-title":"A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders","volume":"17","author":"Murakami","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.coms.2007.01.005_bib52","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"10.1016\/j.coms.2007.01.005_bib53","first-page":"S101","article-title":"Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat","volume":"49","author":"Kapitola","year":"2000","journal-title":"Physiol Res"},{"key":"10.1016\/j.coms.2007.01.005_bib54","first-page":"237","article-title":"Effect of pamidronate on bone blood flow in oophorectomized rats","volume":"47","author":"Kapitola","year":"1998","journal-title":"Physiol Res"},{"key":"10.1016\/j.coms.2007.01.005_bib55","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.coms.2007.01.005_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2007.01.005_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.coms.2007.01.005_bib58","series-title":"Bone health and osteoporosis: a report of the Surgeon General","author":"Office of the Surgeon General","year":"2004"},{"key":"10.1016\/j.coms.2007.01.005_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s001980200033","article-title":"Direct medical costs attributable to osteoporotic fractures","volume":"13","author":"Gabriel","year":"2002","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.coms.2007.01.005_bib60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","article-title":"Postmenopausal osteoporosis","volume":"353","author":"Rosen","year":"2005","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.coms.2007.01.005_bib61","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2007.01.005_bib62","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age: early postmenopausal intervention cohort study group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coms.2007.01.005_bib63","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study randomized, controlled trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coms.2007.01.005_bib64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"10.1016\/j.coms.2007.01.005_bib65","first-page":"S287","article-title":"Risedronate reduces hip fractures in patients with low femoral neck bone mineral density","volume":"42","author":"Miller","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coms.2007.01.005_bib66","series-title":"GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5","author":"Ferlay","year":"2001"},{"key":"10.1016\/j.coms.2007.01.005_bib67","doi-asserted-by":"crossref","unstructured":"RE Coleman. Metastatic bone disease clinical features, pathophysiology and treatment strategies, Cancer Treat Rev 27 (2001), 165\u2013176.","DOI":"10.1053\/ctrv.2000.0210"},{"issue":"Suppl","key":"10.1016\/j.coms.2007.01.005_bib68","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2007.01.005_bib69","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2007.01.005_bib70","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.coms.2007.01.005_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S8756-3282(01)00655-X","volume":"30","author":"Van Beek","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.coms.2007.01.005_bib72","doi-asserted-by":"crossref","unstructured":"Rogers MJ, Gordon S, HL Benfored, et\u00a0al. Cellular and molecular mechanisms of action of bisphosphonates: skeletal complications of malignancy. Cancer 2000;Suppl 88:2961\u20133.","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L"},{"key":"10.1016\/j.coms.2007.01.005_bib73","doi-asserted-by":"crossref","unstructured":"Marx R, Sawatari Y, Fortin M, et\u00a0al. Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567\u201375.","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"10.1016\/j.coms.2007.01.005_bib74","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.637.637","article-title":"The incidence of osteonecrosis of the jaw in patients with multiple myeloma who receive bisphosphonates depends on the type of bisphosphonate","volume":"106","author":"Dimopoulos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3461.3461","article-title":"Bisphosphonates and osteonecrosis of the jaws: incidence in a\u00a0homogeneous series of patients with newly diagnosed multiple myeloma treated with zolendronic acid","volume":"106","author":"Tosi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib76","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.5057.5057","article-title":"Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw","volume":"106","author":"Pozzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.3460.3460","article-title":"Possible role of ozone therapy in the treatment of osteonecrosis of the jaw in multiple myeloma patients","volume":"106","author":"Gallucci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib78","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.5152.5152","article-title":"Osteonecrosis of the jaw associated with chronic bisphosphonate therapy: an Italian experience","volume":"106","author":"Cafro","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coms.2007.01.005_bib79","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Ostonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coms.2007.01.005_bib80","unstructured":"American Dental Association. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. Report of the Council on Scientific Affairs. Chicago (IL): American Dental Association. June, 2006."}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369907000106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369907000106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T10:02:40Z","timestamp":1707904960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369907000106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S1042369907000106"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2007.01.005","relation":{},"ISSN":["1042-3699"],"issn-type":[{"value":"1042-3699","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}